Literature DB >> 9491843

Amphotericin B treatment of fungemia due to unusual pathogens in neutropenic patients: report of two cases.

R Fanci1, P Pecile, R L Martinez, A Fabbri, P Nicoletti.   

Abstract

Invasive fungal infections occur frequently in neutropenic patients although only in recent years has the role of emerging fungi been clearly established. We describe two cases of fungemia caused by Trichosporon beigelii and Rhodotorula glutinis respectively in two neutropenic patients with hematological malignancies who were treated with amphotericin B. The first patient, with refractory multiple myeloma, died following massive pneumonia despite therapy with amphotericin B and granulocyte-colony stimulating factor (G-CSF); the second patient, with relapsed acute lymphatic leukemia and persistent fever without any other clinical evidence, finally recovered. Amphotericin B continues to be considered the "gold standard" in the treatment of invasive mycoses although other approaches need to be tested for refractory infections.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9491843     DOI: 10.1179/joc.1997.9.6.427

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  3 in total

1.  Rhodotorula glutinis-related meningitis.

Authors:  M Lanzafame; G De Checchi; A Parinello; M Trevenzoli; A M Cattelan
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

Review 2.  Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature.

Authors:  Corrado Girmenia; Livio Pagano; Bruno Martino; Domenico D'Antonio; Rosa Fanci; Giorgina Specchia; Lorella Melillo; Massimo Buelli; Giampaolo Pizzarelli; Mario Venditti; Pietro Martino
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 3.  Invasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal Pathogen.

Authors:  João N de Almeida Júnior; Christophe Hennequin
Journal:  Front Microbiol       Date:  2016-10-17       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.